Articles tagged with Melanoma
Levi A. Garraway is being honored for his groundbreaking contributions to cancer research, including the identification of melanoma genes and development of precision oncology approaches. He has also championed parallel sequencing as a definitive approach to tumor genomic profiling, revolutionizing cancer treatment strategies.
The FDA has approved a novel combination therapy of relatlimab and nivolumab for patients with metastatic or inoperable melanoma. The treatment significantly delayed cancer progression time compared to nivolumab alone. LAG-3 blockade reinvigorated T cell anti-tumor activity, establishing the pathway as the third immune checkpoint target.
Researchers from H. Lee Moffitt Cancer Center identified unique features of acral melanoma, including immune checkpoints that could represent novel therapeutic targets for this neglected disease. The study's findings may lead to more effective treatments for patients with acral melanoma.
Researchers found that patients with stage III melanoma who received immunotherapy alone had better rates of distant metastasis-free survival compared to those who underwent completion lymph node dissection. The study suggests that de-escalation of unnecessary therapies, such as CLND, may improve patient outcomes and reduce complications.
Melanoma referral centers worldwide have adopted systemic therapies to treat high-risk melanoma, reducing the need for lymph node removal surgeries. The shift in treatment plans was driven by rapid adoption of effective treatments and a desire to avoid lifelong complications of surgery.
A team of researchers has discovered blood biomarkers that can predict patient response to immunotherapy treatment for melanoma. The study found that patients with increased lactate levels and specific lipid and amino acid metabolites were more likely to respond to treatment.
A pioneering test called AMBLor has been developed to predict the spread or return of skin cancer. By analyzing primary tumor biopsies, the test identifies patients at low risk of disease progression, providing them with more accurate information and personalized prognosis.
The combination of relatlimab and nivolumab doubled progression-free survival benefit compared to nivolumab alone, with significant benefits across pre-specified subgroups. The treatment was associated with a lower risk of disease progression or death.
Patients with sufficient fiber intake had improved progression-free survival and response to immunotherapy in melanoma. A high-fiber diet was associated with slower tumor growth and increased CD4+ T cells in pre-clinical models, supporting the potential benefits of dietary interventions on cancer treatment outcomes.
A research team has identified a bacterium responsible for producing palmerolide A, a melanoma-fighting compound found in Antarctic sea squirts. The discovery could lead to the development of naturally-derived treatments for skin cancer.
CNIO researchers have identified a new biomarker for early melanoma metastasis, proposing the use of NGFR to predict disease prognosis and define risk groups. Blocking NGFR drastically reduces metastasis in mice, paving the way for a potential first treatment to tackle metastasis in its earliest stages.
The CDI laboratory has identified a complex natural pathway that melanoma hijacks to metastasize. The pathway centers around the silencing of bone morphogenetic protein 6 (BMP6), leading to abnormal cell signaling and increased cancer cell motility.
A clinical trial found that giving immunotherapy before targeted therapy improves survival in advanced melanoma patients, with a two-year overall survival rate of 72% compared to 52%. The study suggests that immunotherapy should be the initial approach for treating metastatic melanoma patients, regardless of BRAF mutation status.
A Phase II study shows that combination treatment with nivolumab and ipilimumab improves overall survival in patients with asymptomatic melanoma brain metastases, with an overall survival rate of 71.9% at three years. The treatment demonstrates durable responses, even in symptomatic patients.
Researchers at West Virginia University have received FDA approval for a new drug to treat uveal melanoma, a rare form of eye cancer. The drug, MTI-201, targets specific biomarkers in diseased cells, allowing for more precise treatment with minimal damage to healthy cells.
Researchers found that melanomas detected during routine skin checks were associated with a significantly lower all-cause risk of death, but not melanoma-specific death. The study involved 2,452 patients in Australia and suggests a potential benefit to regular skin cancer screenings.
Metastases in malignant melanoma can use an alternative process to access the circulatory system, where a blood vessel divides into two parallel vessels. This finding challenges traditional research on tumor growth and may lead to new treatment options for metastatic cancer.
Researchers analyzed fecal metagenomic DNA sequencing data to see if specific donor strains correlated with successful treatment outcomes. They found no correlation between donor strains and response to anti-PD-1 therapy in melanoma patients.
Researchers discovered that adrenal gland metastases are unresponsive to checkpoint inhibitors due to the secretion of corticosteroids. Surgical removal is the current best course of action for patients with these metastases. The study's authors hope to develop a nonsurgical treatment option in the future.
The KEYNOTE-716 trial shows that adjuvant pembrolizumab significantly prolongs recurrence-free survival and halves distant recurrences in stage II B/C melanoma patients. This suggests that patients with high-risk stage II melanoma should be offered adjuvant therapy.
Researchers developed a treatment using cowpea mosaic virus nanoparticles that target lung tumors, slowing tumor growth and preventing cancer spread. The treatment showed efficacy against aggressive cancer cell lines and may offer protection to patients at high risk of metastatic disease.
A new combination treatment has shown significant tumor shrinkage and prolonged survival in patients with metastatic uveal melanoma. The treatment, which targets HDAC and PD-1 proteins, was found to work better in tumors with active BAP1 genes, a key discovery that may lead to improved survival rates.
Patients with relapsed metastatic melanoma who received prior anti-PD-1 therapies had a lower response rate to adoptive cell transfer of tumor-infiltrating lymphocytes (ACT-TIL). ACT-TIL was less effective in these patients compared to those who had never received anti-PD-1 therapy. The study found that the objective response rate and ...
Researchers developed a nanotherapeutic platform that combines camptothecin with immune checkpoint inhibitors to increase effectiveness against aggressive tumors. The approach showed promising results in eliminating difficult-to-treat late-stage metastatic colorectal cancer and melanoma tumors.
Researchers found that UVB radiation from the sun causes chemical changes to DNA, leading to disease-causing mutations. This discovery sheds light on the origins of melanoma and highlights the importance of prevention efforts.
A study found specific gut microbiota signatures correlate with high-grade adverse events and response to combined CTLA-4 and PD-1 blockade treatment. The research identified a potential new strategy to treat toxicity while maintaining response through IL-1R inhibition or manipulation of the gut microbiota.
Researchers analyzed molecular analysis data from a pediatric melanoma registry, identifying diverse subgroups and their characteristics. The study found that spitzoid melanomas often have gene fusions and benign clinical courses, while conventional melanoma patients with advanced disease had poorer outcomes.
The partnership aims to reduce the risk of relapse in Stage 2 melanoma patients using BRAF and MEK targeted therapies. EORTC and Pierre Fabre will conduct a large Phase 3 study to advance research in melanoma.
A large clinical trial has shown that pembrolizumab after surgery significantly lowers the risk of disease recurrence in patients with high-risk melanoma. This treatment also results in fewer serious side effects compared to standard therapies like ipilimumab or high-dose interferon.
Haizhen Wang, a MUSC Hollings Cancer Center researcher, has received a $225,000 Young Investigator grant from the Melanoma Research Alliance. She will investigate the function of protein CDK6 in T-cells to improve melanoma therapy outcomes.
A clinical trial found that nearly half of patients treated with nivolumab and ipilimumab were alive six-and-a-half years after treatment, outperforming those who received either drug alone. The combination therapy demonstrated a durable benefit for advanced melanoma patients.
A new study reveals that small uveal melanomas have molecular genetic alterations, making them highly metastatic tumours. Prompt treatment can significantly increase the chances of cure for these patients.
Researchers at H. Lee Moffitt Cancer Center discovered that acral nevi have a distinct mutation profile compared to acral melanoma, with activating mutations in the BRAF gene being very common in acral nevi. The study found that only 10% of patients had activating mutations in the NRAS gene.
A recent study found that banning tanning beds among U.S. minors would significantly reduce the number of melanoma cases in adolescents, with estimates suggesting up to 15,101 cases prevented over the lifetime of 17.1 million minors. The study also estimated that such a ban would save millions of dollars in healthcare costs.
Researchers at the University of Colorado Cancer Center have discovered an NLRP3 inhibitor that can reduce inflammation in melanoma cells, potentially leading to reduced tumor growth and progression. The study's findings suggest that inhibiting NLRP3 could improve patient care for those resistant to checkpoint inhibitors.
Chronic side effects among melanoma survivors after anti-PD-1 immunotherapy treatment are more common than previously recognized, affecting 43% of patients. The most frequently affected organs were joints and the endocrine system.
Pre-clinical study finds NCOA3 activation contributes to melanoma development after exposure to ultraviolet light, promoting survival advantage and accumulation of DNA damage. A single nucleotide polymorphism in NCOA3 decreases protein production, increasing sensitivity to UV-mediated cell death.
A new grant will enable researcher Neil Box to conduct further follow-up work with a longitudinal study of mole development in kids, aiming to determine the effects of early sun exposure. The study aims to develop more sophisticated measures of sun damage and explore its relationship with melanoma risk.
A neural network system analyzes photographs to rank and distinguish suspicious skin lesions, suggesting it can aid clinicians in spotting precancerous marks during clinical visits. The platform's performance was demonstrated with a sensitivity and specificity of 90.3% and 89.9%, respectively, in identifying 'ugly duckling' lesions.
A new study found that altering the gut microbiome can take a patient with advanced melanoma who has never responded to immunotherapy and convert them into responders.
A new AI algorithm has demonstrated the ability to accurately diagnose skin melanoma, rivaling that of experienced dermatologists. The study used machine learning to analyze 937 images and 200 cases, with results showing no significant difference between human dermatologists and the algorithm in making classifications.
A study by Texas A&M University researchers investigated the role of metabolites in melanoma growth and spread. The team found significant differences in metabolite amounts between primary melanoma and surrounding tissues, suggesting that these substances may be responsible for tumor initiation and maintenance.
Increased diagnostic scrutiny is linked to rapid rise in melanoma diagnoses, according to a study published in The New England Journal of Medicine. Melanoma incidence has doubled among adults 65 and older over the past two decades, despite stable mortality rates.
A review of 13 studies found that individuals with skin of color are at increased risk of developing melanoma due to UV exposure. The study suggests that prolonged UV light exposure is a significant risk factor for melanoma in this population.
Researchers analyzed ten cancer patients with refractory melanoma and found that fecal microbiota transplant improved patient outcomes in three out of ten cases. The treatment was safe and feasible, suggesting a potential role in overcoming resistance to anti-PD-1 immunotherapy.
A new study published in the European Society of Human Reproduction and Embryology found that tanning bed use and sunburns may increase a woman's chances of developing endometriosis. The research analyzed data from over 116,000 women and found a higher risk among those who used tanning beds frequently or got sunburnt during teenage years.
A computational method combining clinicodemographic variables and deep learning of pre-treatment histology images accurately predicts response to immune checkpoint blockade. The model, validated in an independent cohort, achieves high accuracy and can stratify patients into high versus low risk for disease progression.
A new study uses artificial intelligence to predict which patients with metastatic melanoma will respond well to immune checkpoint inhibitors. The algorithm achieves an accuracy rate of 80%, outperforming current predictive tools in a significant way.
A new diagnostic system was developed by Lithuanian scientists, achieving over 90% accuracy in detecting melanoma from skin lesions. The non-invasive method combines data from optical spectrophotometry and ultrasound imaging technologies.
Younger patients with resected melanoma showed a benefit from adjuvant bevacizumab treatment, while older patients did not. The study suggests that sFRP2 may promote angiogenesis in older patients with melanoma, which is superseding the role of VEGF.
A key blood marker of cancer could be used to select the most effective treatment for melanoma, according to an Edith Cowan University study. The discovery has the potential to improve melanoma survival rates by identifying patients who may benefit from more aggressive treatments.
A new study has discovered that accumulated DNA damage in skin cells can be used to estimate the risk of deadly skin cancer. Researchers sequenced DNA from individual melanocytes and found a significant number of mutations associated with melanoma, even in people without visible moles.
Researchers found people with pale-colored melanomas are more likely to have an albinism gene mutation, which prevents brown pigment synthesis and increases skin cancer risk. This discovery could lead to personalized medicine and earlier treatment for patients with one mutated albinism gene.
People with pale-colored melanomas are more susceptible to developing rare genetic mutations associated with albinism. Researchers plan to collect samples to compare genotype and develop personalized monitoring for patients with one albinism gene mutation.
A collaborative study has uncovered new markers uniquely present on melanoma tumours that can be recognised by the immune system. These markers, known as spliced peptides, can be used to develop therapeutic vaccines to combat melanoma.
Scientists have discovered a rapid, inexpensive, and non-invasive method to track malignant melanoma using fluorescent molecules in urine samples. The technique allows doctors to diagnose and monitor the disease without requiring invasive biopsies.
A consensus statement evaluates the use of prognostic genetic expression profile testing in melanoma, cautioning against routine use due to limitations. The statement aims to assist clinicians in determining when and how gene expression profiling should be adopted in clinical practice.
Scientists at Sanford Burnham Prebys discovered that PRMT5 inhibitors can sensitize unresponsive melanoma to immune checkpoint therapy, enhancing antigen presentation and innate immunity. The study suggests that these inhibitors may also be effective in tumors of other types, providing a potential breakthrough for cancer treatment.
This study defines the mutation profile of SUM in Caucasians using next-generation sequencing-based genomic analysis, identifying frequently mutated genes. The most abundant mutations were found in KIT and NRAS, while BRAF was only present in 3% of cases, providing insights into the genetics of subungual melanoma.
A study of 34,000 biologic-treated patients found an increased melanoma risk compared to 135,000 conventional therapy patients. The results suggest a potential association between long-term use of biologics for inflammatory diseases and the development of melanoma.